Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma

The treatment of unresectable cholangiocarcinoma (CCA) is limited by the development of resistance to conventional first-line chemotherapy based on gemcitabine (GEM). In addition, a prior treatment with GEM frequently induces cross-resistance to other drugs employed in the second-line. Paclitaxel (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Massa, Annamaria, Peraldo-Neia, Caterina, Vita, Francesca, Varamo, Chiara, Basiricò, Marco, Raggi, Chiara, Bernabei, Paola, Erriquez, Jessica, Sarotto, Ivana, Leone, Francesco, Marchiò, Serena, Cavalloni, Giuliana, Aglietta, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891641/
https://www.ncbi.nlm.nih.gov/pubmed/35251961
http://dx.doi.org/10.3389/fonc.2022.771418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891641/
https://www.ncbi.nlm.nih.gov/pubmed/35251961
http://dx.doi.org/10.3389/fonc.2022.771418

Ejemplares similares